Navigation Links
MDS Inc. Announces Normal Course Issuer Bid
Date:6/30/2008

currently anticipated due to a number of factors, including, but not limited to, successful integration of structural changes, including restructuring plans, acquisitions, technical or manufacturing or distribution issues, the competitive environment for the Company's products, the degree of market penetration of the Company's products, and other factors set forth in reports and other documents filed by the Company with Canadian and US securities regulatory authorities from time to time.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Medical Machines Online Announces the Overstock and Release of a New ECG Machine
2. BMP Sunstone Announces Official Launch of Ferriprox in PRC
3. Elsevier announces 2007 journal impact factor highlights
4. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
5. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
6. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
7. DST Systems, Inc. Announces Notification of Earnings Release Date
8. A Place for Mom, Nations Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance
9. LCA-Vision Announces CFO Change
10. BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
11. Bally Total Fitness Announces New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...blem best diagnosed with combination of assessment...(HealthDay News) -- A combination of blood tests a...effective in finding the cause of a common nerve p...nes issued by the American Academy of Neurology. ... the general population and one in 12 people older...
(Date:12/4/2008)... SecureWorks(R), a leading Security...161% increase in the number of,attempted hacker a...,Attempted attacks increased from an average of 5...s of the year to 133,000 per client per month for ...esent the attack activity for 36 major,retail cor...
(Date:12/4/2008)...Scott Mintzer, M.D., assistant professor in the De... of Thomas Jefferson University, and director of t...ehensive Epilepsy Center of Jefferson Hospital for...igator grant from the National Institutes of Healt...antiepileptic seizure medications. The K23 grant,...
(Date:12/4/2008)... The Neurologic & Orthopedic Ho...sive hospital partner of the Chicago,Red Stars, a...newly formed,league which features the best socce... official partner of the Chicago Red Stars Camps a...eading the medical care for the Red Stars will be ...
Breaking Medicine News(10 mins):Health News:Doctors Issue New Neuropathy Test Guidelines 2Health News:Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks 2Health News:Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks 3Health News:Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks 4Health News:Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks 5Health News:Jefferson researcher awarded NIH grant 2Health News:Neurological & Orthopedic Named Official Hospital of Chicago Red Stars Women's Pro Soccer Team 2
...tional Heart, Lung, and Blood Institute (NHLBI) an...am (NHBPEP),USA, have come out with recommendation...pressure is as important as control of Diastolic b...health care providers, patients, and their familie...
...rt from June issue of the American Journal of Epid...ce higher mortality rates than taller people from ... 30,000 men and women undertaken by Dr.Pekka Jousi... Health Institute in Helsinki, Finland, it was fou...
...not high levels of cholesterol but low levels that...hat Low levels of Cholesterol maybe linked to depr...t men with relatively low cholesterol levels were ... of severe depression. Edward Suarez, PhD from Du...
...Rates Higher for Those Without This Symptom. As ma... prior to or during a heart attack, a study publis...tion suggests. And for women, diabetics and others...al heart attack symptoms, more than half may never...
Other Medicine News:
(Date:12/3/2008)...eatment alleviates long-term anemia and organ dama...s , , MEMPHIS, Tenn., Dec. 3 /PRNewswire-U...orrective gene into mouse blood cells, scientists ...viated sickle cell disease pathology. In their stu...showed essentially no difference from normal mice....
(Date:12/3/2008)...., Dec. 3 Isis Pharmaceu...at OncoGenex Pharmaceuticals, Inc.,provided posit...nical trial of,OGX-011 in combination with doceta...o docetaxel and prednisone alone ("the control arm...e resistant prostate cancer. The current 10.6,mo...
(Date:12/2/2008)... Breast-specific gamma ...ancers not found on mammograms or by,clinical exa...ual meeting of,the Radiological Society of North ...st difficult to detect breast cancer-invasive,lob...M.D., professor of,radiology and director of the ...
(Date:12/2/2008)...ec. 2 Horizon Therapeutics, Inc., ... announced that two pivotal,Phase 3 trials evalua...ZT-501,met all primary endpoints. HZT-501, a nov...ntaining ibuprofen and famotidine, demonstrated a,...nce of non-steroidal,anti-inflammatory drug (NSAI...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Struggling male readers respond better to female teachers 164 1Water Picks Up Odor From Plastic Pipes 163 1Tone Deafness Explained from the Harvard Health Letter 126 1Tone Deafness Explained from the Harvard Health Letter 126 2Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 1Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 2Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 3Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 4Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 5Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 6Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 7Restoring sight advances in fertility treatments and better visibility for pilots at FIO 142 8
...l Findings Reported on Glucose Homeostasis Effects... 2007 /PRNewswire-FirstCall/ -- In a 14-day,Phase... of the,investigational compound dapagliflozin, a ...ter 2 (SGLT2) administered alone or,concomitantly ...o,discontinuations due to adverse events and no se...
...e, June 25, 2007 /PRNewswire/ -- Novagali Pharma, ...ophthalmology,presents positive results of its piv...m the Phase III clinical study of Vekacia(R) in,ch...(VKC) at the,XIV Afro-Asian Congress of ophthalmol...ch (Morocco). , VKC is a severe form of chronic al...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th
Triad Plus PVP-I Scrub swabsticks is formulated with an antimicrobial surgical cleanser containing to prevent dryness. It contains 7.5% PVP-I, USP solution equivalent to 0.75% available iodin
...are saturated with a 10% Povidone Iodine, USP ...vidone Iodine is virtually non-irritating to skin,...g to the skin or natural fabrics. Our swabsticks n...tools for removing small particles from wounds, su...
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness.
Medicine Products: